There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Envelope protein

Envelope protein

Brief Information

Name:Recombinant envelope protein
Target Synonym:env,Submitted name: Recombinant envelope protein,Viral Envelope Proteins
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ENN-C5128 SARS-CoV-2 SARS-CoV-2 (COVID-19) Envelope protein, GST,His Tag

Synonym Name

Envelope protein,Env polyprotein,Envelope glycoprotein,env,COVID-19


The SARS-CoV-2 is composed of a double-layered lipid envelope, including Spike glycoprotein (S), Envelope protein (E), Membrane glycoprotein (M), and Nucleocapsid protein (Nucleocapsid protein, N). Among them, The amino acid sequence of the SARS-CoV-2 envelope protein is 95% identical of the SARS envelope protein.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tecovirimat ST-246; SIGA-246 Approved Siga Technologies Inc Tpoxx United States Smallpox Siga Technologies Inc 2018-07-13 Smallpox; Monkeypox Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PGDM-1400 PGDM-1400 Phase 1 Clinical International Aids Vaccine Initiative HIV Infections Details
Targeting HIV-1 Env gp140 antibodies Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details
Anti-HERV-W humanized monoclonal antibodies (GeNeuro) GNN-001; GNbAC-1; GENHP-01 Phase 2 Clinical Geneuro Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Multiple Sclerosis Details

This web search service is supported by Google Inc.